PDCD1 and melanoma: We designed the BaseTIL trial (CA209-7H9, NCT04165967), a single-center investigator-initiated phase I trial at the University Hospital Basel, Basel, Switzerland, to investigate feasibility and safety of TIL-ACT followed by PD-1 blockade with nivolumab in patients with advanced melanoma.